{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:44:42Z","timestamp":1792525482692,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CM25\/00215"],"award-info":[{"award-number":["CM25\/00215"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["JR23\/00071"],"award-info":[{"award-number":["JR23\/00071"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/01880"],"award-info":[{"award-number":["PI24\/01880"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/01690"],"award-info":[{"award-number":["PI21\/01690"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.arbres.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:29:29Z","timestamp":1792438169000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Partial Echocardiographic Remission After Sotatercept: Expanding Treatment Goals in Pulmonary Arterial Hypertension"],"prefix":"10.1016","author":[{"given":"Eva","family":"Guti\u00e9rrez-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Mart\u00edn de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Cruz Utrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lorena","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Angullo G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"L\u00e1zaro Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Pastor P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Cristo Ropero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Delgado Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Jim\u00e9nez L\u00f3pez-Guarch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Escribano Sub\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.09.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01095-2024","article-title":"Pathology and pathobiology of pulmonary hypertension: current insights and future directions","volume":"64","author":"Guignabert","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.09.004_bib0110","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2026.09.004_bib0115","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.09.004_bib0120","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.09.004_bib0125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","article-title":"Sotatercept for pulmonary arterial hypertension within the first year after diagnosis","volume":"393","author":"McLaughlin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.09.004_bib0130","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.09.004_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2026.02.5103","article-title":"Sotatercept in pulmonary arterial hypertension: central, hematologic, and peripheral mechanisms of benefit","author":"Reddy","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arbres.2026.09.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.09.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.arbres.2026.09.004_bib0150","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70215","article-title":"Progressive pericardial effusions (PEF) in patients with pulmonary arterial hypertension (PAH) taking sotatercept-association with pre-existing pericardial effusion","volume":"15","author":"Subba","year":"2025","journal-title":"Pulm Circ"},{"key":"10.1016\/j.arbres.2026.09.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00768-2025","article-title":"Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH","volume":"66","author":"Hoeper","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.09.004_bib0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2026.09.004_bib0165","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1093\/eurheartj\/ehag023","article-title":"Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up","volume":"47","author":"Ghio","year":"2026","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arbres.2026.09.004_bib0170","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S2213-2600(24)00425-9","article-title":"Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients","volume":"13","author":"Rahaghi","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.09.004_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107577","article-title":"The pleiotropic effects of sotatercept","volume":"162","author":"Manzi","year":"2026","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.arbres.2026.09.004_bib0180","article-title":"Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension","author":"Badagliacca","year":"2017","journal-title":"J Heart Lung Transplant."},{"key":"10.1016\/j.arbres.2026.09.004_bib0185","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacc.2026.02.5103","article-title":"Sotatercept in Pulmonary Arterial Hypertension: Central","volume":"88","author":"Reddy","year":"2026","journal-title":"Hematologic, and Peripheral Mechanisms of Benefit. J Am Coll Cardiol"},{"key":"10.1016\/j.arbres.2026.09.004_bib0190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.chest.2019.09.009","article-title":"Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension","volume":"157","author":"D\u2019Alto","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.09.004_bib0195","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01734-2025","article-title":"Haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension","volume":"12","author":"Cruz-Utrilla","year":"2026","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.arbres.2026.09.004_bib0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1038114","article-title":"Activin A directly impairs human cardiomyocyte contractile function indicating a potential role in heart failure development","volume":"9","author":"MacDonnell","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626003571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626003571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:25:44Z","timestamp":1792524344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626003571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S0300289626003571"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.09.004","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial Echocardiographic Remission After Sotatercept: Expanding Treatment Goals in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}